Atomoxetine and Oxybutynin in Obstructive Sleep Apnea
| Status: | Completed |
|---|---|
| Conditions: | Insomnia Sleep Studies, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 21 - 65 |
| Updated: | 1/31/2019 |
| Start Date: | September 2016 |
| End Date: | January 2018 |
Effect of Atomoxetine and Oxybutynin on Phenotype Traits and OSA Severity
Obstructive sleep apnea (OSA) is common and has major health implications but treatment
options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
to normal subjects. Until recently, the search for medicines to activate pharyngeal muscles
in sleeping humans has been discouraging. However, exciting new animal research has shown
that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle
activity to waking levels. In this protocol the investigators will test the effect of
atomoxetine (a norepinephrine reuptake inhibitor) and oxybutynin (an antimuscarinic drug)
administered together on OSA phenotype traits and OSA severity during sleep.
options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle
activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared
to normal subjects. Until recently, the search for medicines to activate pharyngeal muscles
in sleeping humans has been discouraging. However, exciting new animal research has shown
that drugs with noradrenergic and antimuscarinic effects can restore pharyngeal muscle
activity to waking levels. In this protocol the investigators will test the effect of
atomoxetine (a norepinephrine reuptake inhibitor) and oxybutynin (an antimuscarinic drug)
administered together on OSA phenotype traits and OSA severity during sleep.
Inclusion Criterion:
- AHI > 20
Exclusion Criteria:
- Any medical condition other than well controlled hypertension.
- Any medication known to influence breathing, sleep/arousal or muscle physiology.
- Claustrophobia.
- Inability to sleep supine.
- Allergy to lidocaine, Oxymetazoline HCl, atomoxetine/oxybutynin.
- Individuals with underlying cardiac disease, such as arrhythmias.
- Individuals taking psychiatric medications, such as atomoxetine, or any of the studied
medications for medical care.
- History of seizures
- For women: Pregnancy.
- History of panic disorder / hyperventilation syndrome / Attention
deficit-hyperactivity disorder (ADHD) / autism
We found this trial at
1
site
Click here to add this to my saved trials
